Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.

The 24th Annual Meeting of China Association for Science and Technology (CAST): Sansure Biotech Awarded by CAST
2022-06-29

On June 26 and 27, the 24th annual meeting of China Association for Science and Technology (CAST) themed “Led by Innovation, Self-reliance-Building A New Engine of the Rise of Central China” jointly hosted by CAST and Hunan Provincial People’s Government was held in Changsha, Hunan. In the annual meeting, Sansure Biotech was awarded with the plaque of Enterprise Association of […]

LEARN MORE
Ambassadors of Malawi to China visited Sansure Biotech
2022-06-28

Accompanied by the management from Office of Foreign Affairs Commission of CPC Hunan Provincial Committee, H.E. Allan Chintedza, the Ambassador of Malawi to China, and Oliver Kingstone Chimphambano, the Deputy Ambassador of Malawi to China, visited Sansure Biotech on June 23rd. Dr. Lizhong Dai, the Chairman of Sansure Biotech was also along with the visit. Ambassador Allan Chintedza visited the […]

LEARN MORE
British Consul General in Guangzhou visited Sansure Biotech
2022-06-24

On June 20, Jo Hawley, the British Consul General in Guangzhou, and Mr. Mike McCourt, Healthcare Director in China for the British Department of International Trade China, visited Sansure Biothech. They were accompanied by the management from Changsha High-Tech Development Zone, along with Dr. Lizhong Dai, the Chairman of Sansure. During the visit, they had an in-depth discussion on further […]

LEARN MORE
Sansure Obtains CE Mark under IVDR Certification for New POCT iPonatic S-Q36A
2022-06-10

On June 7, the new generation of iPonatic full-automatic nucleic acid testing and analysis system of Sansure Biotech was certified by IVDR CE, which will better serve the construction of public health prevention and control system globally. CE certification is mandatory for product access to the EU market. From May 26, 2022, the EU comprehensively implemented in vitro diagnosis medical […]

LEARN MORE
Focusing on Screening and early detection of cancer, Sansure Biotech and Singlera Genomics have reached a strategic cooperation
2022-06-09

On June 8, Singlera Genomics (Shanghai) Ltd. (hereinafter referred to as “Singlera Genomics”) announced that it had completed a 300 million yuan B+ round of financing. This round of financing is led by Forestone Capital, followed by funds from Yinhe Yuanhui, Guojing Capital, Junci Investment, Qiandao Investment, Best, Brilliance Investment. As a strategic investor, Sansure Biotech followed the investment, and […]

LEARN MORE
1 2 3 7
×
Get in touch with us
I confirm that I have reviewed Sansure's Privacy Policy and agree with the collection and storage of my personal data.
SUBMIT

Thank you!

We shall contact you soon!